Trials / Completed

CompletedNCT02182570

WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients

Phase III Open-labeled Study of WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 62 (actual)

Sponsor: Boehringer Ingelheim · Industry
Sex: All
Age: 15 Years
Healthy volunteers: Not accepted

Summary

The safety and efficacy of WAL 801 CL (epinastine hydrochloride) Dry Syrup in the treatment of atopic dermatitis in children was evaluated and plasma drug concentrations were measured.

Conditions

Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	WAL 801 CL dry syrup

Timeline

Start date: 2001-06-01
Primary completion: 2002-02-01
First posted: 2014-07-08
Last updated: 2014-07-14

Source: ClinicalTrials.gov record NCT02182570. Inclusion in this directory is not an endorsement.